Phase I/II Study of Combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Alisertib (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 18 Apr 2016 Status changed from active, no longer recruiting to completed.
- 25 Jan 2013 New source identified and integrated (Mayo Clinic, 08-006317).
- 09 Oct 2012 Planned End Date changed from 1 Nov 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.